ArticleJournal of radiation research2026
NOP58 modulates radiosensitivity in non-small cell lung cancer via DDX18-mediated DNA damage repair.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) constitutes 80-85% of lung cancers, with advanced cases showing a 20-30% 5-year survival rate. Radiation resistance limits radiotherapy efficacy, and the function of NOP58 in this process is unknown. This study investigated the mechanisms of NOP58 in NSCLC radioresistance. A radiation-resistant NSCLC cell line (H1299R) was established. Bioinformatic analysis of the Cancer Genome Atlas Program data revealed that high NOP58 expression correlates with poor patient prognosis. The expression levels of NOP58 and DDX18 expression were quantified via quantitative real-time polymerase chain reaction and Western blot. Radiosensitivity of H1299R cells and parental H1299 cells was assessed under irradiation (0, 2, 4, 6 and 8 Gy). Cell viability was assessed using cell counting kit-8 and colony formation assays. Apoptosis was detected by flow cytometry with Annexin V/PI staining. DNA damage was analyzed via γ-H2AX immunofluorescence and comet assays. NOP58 knockdown and DDX18 overexpression were performed for rescue experiments, and protein interaction was validated by pull-down assays. NOP58 and DDX18 were significantly upregulated in H1299R cells. H1299R cells exhibited higher cell viability, stronger colony-forming capacity, reduced apoptosis and less DNA damage under irradiation treatment. The depletion of NOP58 in H1299 and H1299R cells exacerbated radiation-induced DNA damage, reduced cell viability and promoted apoptosis, reversing radioresistance. Direct interaction between NOP58 and DDX18 was confirmed by pull-down assay. DDX18 overexpression reversed the radiosensitizing effects of NOP58 knockdown, including attenuated DNA damage and restored cell survival. Overexpression NOP58 converted radiosensitive cells to a resistant phenotype. NOP58 promotes NSCLC radioresistance by interacting with DDX18, regulating its expression and thereby suppressing radiation-induced DNA damage. The NOP58-DDX18 axis could be a promising therapeutic target for improving radiotherapy efficacy in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.